NCT03744468 · Interventional trial
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
Overall registry status Completed
Phase 1 · Phase 2
Conditions HNSCC for Phase 2 Dose Expansion, Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, NSCLC for Phase 2 Dose Expansion
Delaware Valley sites
- Fox Chase Cancer Center · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory